This article is more than 5 years old. Information may no longer be current.
ACIP recommends 9-valent HPV vaccine for routine immunization
Click Here to Manage Email Alerts
A 9-valent HPV vaccine is now recommended by the CDC’s Advisory Committee on Immunization Practices as one of the three HPV vaccines that can be used for routine vaccination.
Gardasil 9 (9vHPV, Merck) was approved by the FDA in December 2014 for use among females aged 9 through 26 years and males aged 9 through 15 years. It contains HPV 6, 11, 16 and 18 virus-like particles, similar to the quadrivalent HPV vaccine, as well as HPV 31, 33, 45, 52 and 58 virus-like particles.
Prior to giving their recommendation, the ACIP reviewed data from a randomized trial among approximately 14,000 females aged 16 through 26 years. Study results indicated the 9-valent HPV vaccine had comparable immunogenicity for HPV types 6, 11, 16 and 18 vs. the quadrivalent HPV vaccine and high efficacy for the five additional types. Other studies in the 9-valent HPV vaccine clinical development program assessed antibody response among different age groups and males and females.
As a result, the ACIP states that the 9-valent, quadrivalent and bivalent HPV vaccines can be used for routine vaccination of females aged 11 or 12 years as well as females aged through 26 years who have not been previously vaccinated or have not completed the three-dose series.
The 9-valent or quadrivalent HPV vaccines can be used for routine vaccination of males aged 11 or 12 years and males aged through 21 years who have not been previously vaccinated or have not completed the three-dose series, according to the committee.
For immunocompromised patients and men who have sex with men aged 26 years or younger who have not been previously vaccinated, the ACIP recommends vaccination with the 9-valent or quadrivalent HPV vaccine.
“A clinical trial is ongoing to assess alternative dosing schedules of 9vHPV,” Emiko Petrosky, MD, of the CDC’s Epidemic Intelligence Service, and colleagues wrote in MMWR. “ACIP will formally review the results as data become available. HPV vaccination should not be delayed pending availability of 9vHPV or of future clinical trial data.” – by Amanda Oldt
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts